Althea Technologies provides services that help drug developers speed up the drug discovery and testing process, as well as reduce risks and costs associated with research and development efforts. Founded in 1998 by co-chairs Francois Ferre and Magda Marquet -- who hold Ph.D.s in molecular oncology and biochemical engineering -- the company assists in the development process from discovery through testing, regulatory support, and contract manufacturing stages. Services include gene expression analysis, protein production, and therapeutic and vaccine product manufacturing for clinical trials.

Haw Par Corporation Limited is engaged in licensing the Tiger trademarks, and owning investments for long-term holding purposes. It has four segments: manufacturing, marketing and trading of Healthcare products; provision of leisure-related services; property rental, and investments in securities. Its healthcare division principally manufactures and distributes analgesic products under the Tiger Balm and Kwan Loong brand. Leisure division provides family and tourist oriented leisure alternatives mainly in the form of oceanariums. Property division owns and leases out several investment properties in the Asia region. Investment division engages in investing activities, mainly in quoted and unquoted securities in Asia region. In December 2009, the Company announced that it completed the dissolution of the subsidiaries Haw Par Realty Private Limited, HPH Property Sdn Bhd, Kwan Loong Industries Sdn Bhd, Haw Par Tiger Balm (Hong Kong) Limited and Kwan Loong Oils (HK) Limited.

AstraZeneca Czech Republic is a subsidiary of the international pharmaceutical behemoth known as AstraZeneca. It markets products such as heartburn reliever Nexium, local anesthetic Xylocaine, and endometriosis treatment Zoladex in the Czech Republic. It also conducts clinical trials on potential drug candidates in other parts of Central and Eastern Europe, such as Bulgaria, Hungary, Poland, Romania, and Slovenia. It focuses its research efforts primarily on the medical fields of gastroenterology, gynecology, and oncology, as well as bone and joint, cardiovascular, infectious, and respiratory diseases.

Genetix Group plc, along with its subsidiaries, is engaged in the design, development, manufacture and marketing of automated systems, services and consumables for cell biology, cytogenetics, pathology, proteomic and genomic research worldwide. The biopharmaceutical family of products include the ClonePixFL and associated reagents, which are used to identify the antibody clones that form the basis of pharmaceutical drugs. The ClonePix FL is also used to identify high-yielding cell lines for a customer’s production process. Its Cytovision systems are used worldwide for both pre and post natal genetic testing, and identifying certain forms of cancer, such as leukemia. Its Ariol system is used to image tissue samples from patients. Its wholly owned subsidiaries include Genetix Limited, Genescreen Limited, Genpak Limited, Genetix GmbH and Genetix KK. In April 2009, the Company acquired SlidePath Limited. In January 2010, Danaher Corporation acquired 97% interest in the Company.

Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts. Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. The company develops Zemiva, a molecular imaging pharmaceutical product, which completed Phase II clinical trail for the diagnosis of cardiac ischemia or insufficient blood flow to the heart; and Trofex, a preclinical trail product for the detection of metastatic prostate cancer. Its molecular radiotherapeutic oncology product candidates under development include Azedra that completed Phase I clinical trail for the treatment of pheochromocytoma in adults and neuroblastoma in children; Onalta, a Phase II clinical trail product for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors; and Solazed, a preclinical trail product for the treatment of malignant metastatic melanoma. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003.

The National Institutes of Health (NIH), through its own research and the distribution of grants, seeks to understand disease inside and out. Part of the US Department of Health and Human Services, the NIH is the government's main medical research entity. It comprises 27 institutes and centers covering every medical discipline, from general medical sciences to alternative therapies. The organization has nearly 6,000 scientists of its own and gives out some 50,000 grants to researchers at more than 3,000 universities, hospitals, and research labs in all 50 states. Among its vast array of projects, NIH has supported efforts to develop an AIDS vaccine, map human genetic variation, and study avian flu.

Atrium Innovations (formerly Atrium Biotechnologies) believes you are what you eat. Or rather, you are what you take! The company manufactures and markets more than 1,300 vitamins, minerals, and nutritional supplements geared toward alternative health consumers. Its Pure Encapsulations line of vitamin and herbal extract capsules are a premium brand of natural hypoallergenic products. The company sells products to health care professionals in more than 35 countries, primarily in North America and Europe, through its direct sales and marketing network.

Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. Dyax Corp. (Dyax) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company uses the drug discovery technology, known as phage display, to identify antibody, small protein and peptide compounds for clinical development. The Company’s product DX-88 (ecallantide), is in late stage clinical trial development in two separate indications. In addition to DX-88, the phage display technology has allowed Dyax to develop a substantial pipeline of drug candidates. In June 2008, the Company completed a second phase three study, known as EDEMA4.

Affymax, Inc. company was founded in 2001 and is based in Palo Alto, California. Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company’s lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide.

Taconic Farms, Inc. company provides research rodents and related products and services to research facilities and medical laboratories in Asia, Europe, and North America. Taconic's rats and mice are the workhorses of the biomedical industry and specially bred to be disease-free or genetically modified to exhibit certain traits to help researchers develop new therapies for human disease. Other divisions within the company offer monoclonal antibody production, and drug- and animal-safety testing. It has operations in Denmark, Germany, and the US. Family-owned Taconic was founded in 1952 by Robert Phelan.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.